UBS analyst Colin Bristow lowered the firm’s price target on ALX Oncology to $29 from $31 and keeps a Buy rating on the shares. The firm updated its model for the company following its Q4 report. UBS said the price target decrease is based on a DCF valuation, supported by a sum-of-the-parts EV:Sales methodology.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALXO:
- ALX Oncology, Quantum Leap dose first patient in I-SPY-P1 trial
- ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer
- ALX Oncology price target lowered to $30 from $65 at H.C. Wainwright
- ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
- ALX Oncology announces first patient dosed in ASPEN-07 study
